<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526953</url>
  </required_header>
  <id_info>
    <org_study_id>SCAC-001</org_study_id>
    <nct_id>NCT02526953</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients</brief_title>
  <official_title>Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of paclitaxel,&#xD;
      capecitabine, mitomycin and intensity-modulated radiotherapy is more effective than the&#xD;
      standard combination of capecitabine, mitomycin and intensity-modulated radiotherapy (IMRT)&#xD;
      in patients with squamous-cell anal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial aims to investigate the efficacy of chemoradiotherapy with or without paclitaxel&#xD;
      in squamous-cell anal cancer. This is a prospective multicenter open-label randomized phase&#xD;
      III clinical trial. Patients will be randomized using an online randomization system to&#xD;
      receive either standard IMRT with capecitabine and mitomycin or IMRT with capecitabine,&#xD;
      mitomycin and paclitaxel. A stratification will be performed based on T stage, N stage and&#xD;
      clinical center. Doses of capecitabine and mitomycin in experimental group were reduced for&#xD;
      better treatment tolerance. The target accrual is 157 patients in each treatment arm&#xD;
      (including 10% potential data loss) based on potential benefit of 15% 3-yr disease-free&#xD;
      survival (70% vs 85%), α=0,05, power 80% in the experimental arm. An interim analysis is&#xD;
      planned after 50% of the patients will reach a 3-year followup. Pelvic Magnetic Resonance&#xD;
      Imaging (MRI) is performed in all patients for staging and followup. Pelvic MRI and&#xD;
      histological diagnosis are subject to central review. Conduction of this study and data&#xD;
      collection are controlled by a local institutional board.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response at 26 weeks</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year colostomy-free survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year cancer-specific survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity measured according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.4.0</measure>
    <time_frame>30 days</time_frame>
    <description>Toxicity measured according to NCI-CTCAE v.4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity measured according to Radiation Therapy Oncology Group (RTOG) criteria</measure>
    <time_frame>3 years</time_frame>
    <description>Late toxicity measured according to RTOG criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of life according to European organization for research and treatment of cancer (EORTC) Quality of Life questionnaire (QLQ)-C30 (v.3) scale</measure>
    <time_frame>3 years</time_frame>
    <description>Change from baseline in quality of life on the EORTC QLQ-C30 (v.3) scale</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Anus Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Anus Diseases</condition>
  <condition>Neoplasms</condition>
  <condition>Neoplasms, Squamous Cell</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>(2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-{[(2R,3S)- 3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}- 1,7-dihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycins</intervention_name>
    <description>10 mg/m2, IV, on day 1. Number of infusions: 1.</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Mitomycin C</other_name>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycins</intervention_name>
    <description>12 mg/m2, IV, on day 1. Number of infusions: 1.</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>Mitomycin C</other_name>
    <other_name>MMC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Histologically verified squamous-cell anal cancer&#xD;
&#xD;
          -  Stage I-IIIB (Union for International Cancer Control (UICC) TNM classification v7)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) status 0-2&#xD;
&#xD;
          -  HIV (Human Immunodeficiency Virus) negative&#xD;
&#xD;
          -  Haemoglobin (HGB) &gt; 90 g/L&#xD;
&#xD;
          -  Platelet Count (PLT) &gt; 120x10*9/L&#xD;
&#xD;
          -  Serum creatinine &lt; 150 µmol/L&#xD;
&#xD;
          -  Total bilirubin &lt; 25 µmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to obtain informed consent&#xD;
&#xD;
          -  distant metastases&#xD;
&#xD;
          -  synchronous or metachronous tumors&#xD;
&#xD;
          -  previous chemotherapy or radiotherapy&#xD;
&#xD;
          -  clinically significant cardiovascular disorders (myocardial infarction &lt; 6 months&#xD;
             before visit, stroke &lt; &lt; 6 months before visit, instable angina &lt; 3 months before&#xD;
             visit, arrhythmia, uncontrolled hypertension &gt; 160/100 mm hg&#xD;
&#xD;
          -  clinically significant neurological disorders&#xD;
&#xD;
          -  previous neuropathy 2 or higher&#xD;
&#xD;
          -  current infection or heavy systemic disease&#xD;
&#xD;
          -  pregnancy, breastfeeding&#xD;
&#xD;
          -  ulcerative colitis&#xD;
&#xD;
          -  individual intolerance to treatment components&#xD;
&#xD;
          -  proven dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          -  participation in other clinical trials&#xD;
&#xD;
          -  psychiatric disorders, which render patient unable to follow instructions or&#xD;
             understand his/her condition&#xD;
&#xD;
          -  technical inability to perform pelvic MRI&#xD;
&#xD;
          -  inability of long-term followup of the patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arsen O Rasulov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>N.N.Blokhin Russian Cancer Research Center</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 15, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>February 7, 2021</last_update_submitted>
  <last_update_submitted_qc>February 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Sergey Gordeyev</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>anal cancer</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>intensity-modulated radiotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
    <mesh_term>Anus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

